COMPASS Pathways (NASDAQ:CMPS) Receives Buy Rating from HC Wainwright

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $45.00 price target on the stock.

Other equities analysts have also issued research reports about the company. Royal Bank of Canada restated an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a “buy” rating and a $11.00 target price for the company. Finally, Canaccord Genuity Group reduced their target price on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $4.04 on Tuesday. COMPASS Pathways has a 12 month low of $3.17 and a 12 month high of $11.72. The stock has a fifty day moving average price of $4.05 and a 200-day moving average price of $5.18. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a market cap of $276.42 million, a PE ratio of -1.84 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). Equities research analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On COMPASS Pathways

Institutional investors have recently modified their holdings of the stock. RTW Investments LP acquired a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $11,714,000. Altium Capital Management LLC acquired a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $5,384,000. Nantahala Capital Management LLC grew its position in shares of COMPASS Pathways by 400.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $3,780,000 after acquiring an additional 800,000 shares during the period. Tang Capital Management LLC acquired a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $3,780,000. Finally, Sio Capital Management LLC grew its position in shares of COMPASS Pathways by 211.7% during the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after acquiring an additional 621,222 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.